Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation.
Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation.
复制标题
外照射后 5 年前列腺癌得到控制的临床和生化证据。
DOI：
10.1097/00005392-199508000-00032
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Schultheiss,TE
中科院分区：
文献类型：
--
作者：
Hanks,GE;Lee,WR;Schultheiss,TE
PurposeWe证明了5年的生存率与前列腺癌患者的放射治疗，适形技术和前列腺特异性抗原（PSA）的倍增时间的价值后，radiation.Materials和MethodsThe结果的502例连续T1至T3期前列腺癌放疗单独治疗。PSA倍增时间之前和失败后的13例患者和治疗后PSA倍增时间的报告为93个连续的患者中，放射failed.ResultsThe精算生存与生化自由疾病（PSA最低点1.5或更少不增加）在5年为44%，为所有患者，50%的适形治疗组和39%的常规治疗组。放射治疗失败后PSA倍增时间是可变的，42%大于12 months.ConclusionsThe 5年生存率为前列腺癌患者接受放射治疗是极好的。适形技术上级于常规治疗，并且没有证据表明放射加速前列腺癌的生长速度。
PurposeWe demonstrate the 5-year survival rate for patients with prostate cancer treated by irradiation, the value of the conformal technique and prostate specific antigen (PSA) doubling times after irradiation.Materials and MethodsThe outcome of 502 consecutive patients with stages T1 to T3 prostate cancer treated by irradiation alone is reported. PSA doubling times before and after failure are reported for 13 patients and posttreatment PSA doubling times are reported for 93 consecutive patients in whom radiation failed.ResultsThe actuarial survival with biochemical freedom from disease (PSA nadir 1.5 or less not increasing) at 5 years was 44 percent for all patients, 50 percent for the conformal treatment group and 39 percent for the conventional therapy group. PSA doubling times after radiation failure were variable, with 42 percent greater than 12 months.ConclusionsThe 5-year survival rate for patients with prostate cancer treated by irradiation is excellent. The conformal technique is superior to conventional therapy and there is no evidence that irradiation accelerates the growth rate of prostate cancer.